Lasting effect of pazopanib in first-line treatment of renal cell carcinoma

Abstract

Pazopanib is registered with the European Medicines Agency (EMA) for the treatment of metastatic renal cell carcinoma. Pazopanib is an orally administered potent tyrosine kinase inhibitor.

Keywords

• Pazopanib
• antineoplastic agents
• tyrosine kinase inhibitors
• kidney cancer
• metastases